Syros to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 15, 2022

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) is set to host a live conference call and webcast on March 15, 2022, at 8:30 a.m. ET, to discuss its fourth quarter and full year 2021 financial results. The call can be accessed via phone at (866) 595-4538 for domestic calls and (636) 812-6496 internationally, using conference ID 9682507. Syros is advancing a clinical-stage pipeline with key products like tamibarotene and SY-2101 targeting myeloid malignancies and acute promyelocytic leukemia, respectively. A webcast will be available for 30 days post-event on Syros’ website.

Positive

• Advancing a clinical-stage pipeline with promising candidates like tamibarotene and SY-2101.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, March 15, 2022 to report its fourth quarter and full year 2021 financial results and provide a corporate update.

To access the live conference call, please dial (866) 595-4538 (domestic) or (636) 812-6496 (international) and refer to conference ID 9682507. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors and blood cancers. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005033/en/

Media:

Courtney Solberg

Syros Pharmaceuticals

917-698-9253

csolberg@syros.com

Investor:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

When will Syros Pharmaceuticals report its fourth quarter and full year 2021 financial results?

Syros Pharmaceuticals will report its fourth quarter and full year 2021 financial results on March 15, 2022.

How can I access the Syros Pharmaceuticals conference call?

The conference call can be accessed by dialing (866) 595-4538 domestically or (636) 812-6496 internationally, with conference ID 9682507.

What is the focus of Syros Pharmaceuticals' clinical pipeline?

Syros Pharmaceuticals is focused on developing small molecule therapies targeting gene expression in oncology, specifically for conditions like myelodysplastic syndrome and acute myeloid leukemia.

Where can I find the webcast of the Syros Pharmaceuticals conference call?

The webcast will be available in the Investors & Media section of Syros' website at www.syros.com.